Akshit Chitkara, MD, discusses outcomes with IO doublet therapy by dedifferentiation status and histologic grade in ccRCC.
Akshit Chitkara, MD
Advertisement
Akshit Chitkara, MD, is a hematology-oncology fellow at Sidney Kimmel Cancer Center.
Articles by Akshit Chitkara, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
5